Understanding how hybrid peptides affect insulin-producing cells in diabetes
Characterize the Landscape and Origin of Hybrid Peptides in Beta Cells
This study is looking at how certain modified proteins called hybrid insulin peptides might cause the immune system to mistakenly attack the insulin-producing cells in people with Type 1 Diabetes, and it hopes to find new ways to understand and treat the condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado Denver NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project ID | NIH-10911850 on NIH RePORTER |
What this research studies
This research investigates the role of hybrid insulin peptides (HIPs) in Type 1 Diabetes (T1D), focusing on how these modified proteins may trigger the immune system to attack insulin-producing beta cells. By studying the presence of HIPs in both animal models and human patients, the research aims to uncover the mechanisms behind the autoimmune response in T1D. The team will utilize advanced techniques, including mass spectrometry, to analyze beta cells and assess the impact of autophagy on HIP levels. This could lead to new insights into the disease and potential therapeutic targets.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Type 1 Diabetes, particularly those with recent onset of the disease.
Not a fit: Patients with Type 2 Diabetes or other forms of diabetes unrelated to autoimmune mechanisms may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved understanding and treatment options for patients with Type 1 Diabetes.
How similar studies have performed: Previous research has shown promising results in understanding autoimmune responses in diabetes, suggesting that this approach could yield valuable insights.
Where this research is happening
Aurora, UNITED STATES
- University of Colorado Denver — Aurora, United States (Active)
Researchers
- Principal investigator: Delong, Thomas — University of Colorado Denver
- Study coordinator: Delong, Thomas
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.